that mediate TNF's anticancer effects from its lethal proinflammatory effects, which have so far hindered its use as an anticancer drug. The researchers uncover cellular mechanisms with differential sensitivity to TNF upon reduction of its receptor (p55TNFR) and demonstrate proof of principle by reducing melanoma tumors in mice by administering TNF and simultaneously decreasing TNF receptor levels. [JCI] Press release: Greek, English